Peter J. Werth is Founder and CEO of ChemWerth Inc., a privately held Connecticut-based corporation founded in 1982. ChemWerth Inc. is a full-service generic drug development and supply company providing high quality Active Pharmaceutical Ingredients to regulated markets worldwide. Through exclusive development and partnerships with API manufacturers, ChemWerth Inc. provides expertise in product selection and development, analytical and regulatory services, and strong project management to ensure the highest standards of quality.
With operations in China and India, ChemWerth was one of the first companies to recognize China’s potential to be a major supplier of generic APIs to the U.S. By 1986, ChemWerth received FDA approval for its first product from China.
Mr. Werth began his career working on the chemical side of the generic drug business from its inception in 1975 in the areas of Research and Development as well as Sales and Marketing. From 1965 to 1975, he worked in Research and Development for Upjohn Pharmaceuticals, now Pfizer. Prior to starting ChemWerth he was with Ganes Chemicals, a subsidiary of Siegfried Chemicals, where he was Vice President of Sales and Marketing for their U.S. operations.
Mr. Werth envisioned the ability to develop and implement a successful business model for project selection which he believed was the heart of a successful generic company. Following this business model, ChemWerth has successfully introduced over 130 generic APIs.
Mr. Werth earned a BS degree in Chemistry and Math from Fort Hays State University and a MS degree in Organic Chemistry from Stanford University. He serves as a board of director for the following companies: VM Pharma LLC, VM Therapeutics LLC, VM Oncology LLC, Likarda LLC, Altos Therapeutic, Alzeca, Nuance, Perseus and Cingulate Therapeutics LLC. Mr. Werth has formed LLCs to develop commercial projects using specific technologies which reflect his strong entrepreneurial interests and contributions toward start-ups. Mr. Werth was the lead investor in the first two companies that targeted generics for companion animals – Putney and Piedmont.
Along with his family, he has established the Werth Family Foundation to support various philanthropic causes, specifically in educational, cultural, and medical-related causes globally. Mr. Werth financed the formation of The Peter J. Werth Institute for Entrepreneurship and Innovation at the University of Connecticut, the Werth College of Science, Technology and Mathematics at Fort Hays State University and the Werth Center for Coastal & Marine Studies at Southern Connecticut State University.
What is Peter J. Werth's net worth?
The estimated net worth of Peter J. Werth is at least $610.15 thousand as of February 6th, 2026. Mr. Werth owns 117,449 shares of Cingulate stock worth more than $610,148 as of September 18th. This net worth approximation does not reflect any other assets that Mr. Werth may own. Learn More about Peter J. Werth's net worth.
How do I contact Peter J. Werth?
Has Peter J. Werth been buying or selling shares of Cingulate?
Peter J. Werth has not been actively trading shares of Cingulate within the last three months. Most recently, on Friday, February 6th, Peter J. Werth bought 19,455 shares of Cingulate stock. The stock was acquired at an average cost of $5.04 per share, with a total value of $98,053.20. Following the completion of the transaction, the director now directly owns 117,449 shares of the company's stock, valued at $591,942.96. Learn More on Peter J. Werth's trading history.
Who are Cingulate's active insiders?
Are insiders buying or selling shares of Cingulate?
In the last year, Cingulate insiders bought shares 5 times. They purchased a total of 130,350 shares worth more than $656,964.00. The most recent insider tranaction occured on February, 13th when Director Thomas Jeffrey Hargroves bought 97,276 shares worth more than $490,271.04. Insiders at Cingulate own 5.3% of the company.
Learn More about insider trades at Cingulate. Information on this page was last updated on 2/13/2026.
